Peptide Profile
Thymosin Alpha-1
What Is Thymosin Alpha-1?
Thymosin alpha-1 is a naturally occurring 28-amino acid peptide originally isolated from thymosin fraction 5 — a partially purified extract of calf thymus tissue — by Allan Goldstein and colleagues at George Washington University during the 1970s.[1][8] The peptide is N-terminally acetylated, has the molecular formula C129H215N33O55, a molecular weight of approximately 3,108 g/mol, and is registered under CAS number 62304-98-7.
The synthetic version of thymosin alpha 1, known as thymalfasin (marketed under the trade name Zadaxin), is manufactured as a chemically identical replica of the endogenous peptide. Thymalfasin has been approved in over 35 countries — primarily in Asia, South America, and parts of Europe — for the treatment of chronic hepatitis B and hepatitis C, as a vaccine adjuvant in immunocompromised populations, and for general immune support in clinical settings.[1][8] It is not approved by the FDA or MHRA for therapeutic use.
The thymus gland, from which thymosin alpha-1 derives its name and was first identified, plays a central role in T-cell development and immune system education. Thymic output declines with age (a process termed thymic involution), and research interest in Tα1 has partly been driven by the hypothesis that supplementing this thymic peptide could partially compensate for age-related immune decline.[1][9]
Compound Profile
Mechanism of Action
The mechanism of action of thymosin alpha-1 operates through multiple interconnected immunological pathways, affecting both innate and adaptive immune responses.[2][3][4]
T-cell maturation and differentiation. Tα1 promotes the maturation of T-cell precursors (thymocytes) into functional T-cells, enhancing the expression of T-cell markers including CD3, CD4, and CD8. This effect supports the development of both helper and cytotoxic T-cell populations, strengthening adaptive immune surveillance.[1][2][8]
Dendritic cell activation. The thymosin alpha 1 peptide activates dendritic cells (DCs) — the principal antigen-presenting cells responsible for initiating adaptive immune responses. Romani et al. (2007) demonstrated that Tα1 promotes DC maturation and function through Toll-like receptor-dependent pathways, enhancing antigen presentation and the subsequent activation of T-cell responses.[2] This dendritic cell activation represents a key mechanism by which Tα1 bridges innate pathogen detection with adaptive immune activation.
Toll-like receptor signalling. Thymosin alpha-1 acts as an endogenous activator of Toll-like receptor (TLR) signalling, particularly TLR2 and TLR9. Bozza et al. (2007) demonstrated that Tα1 activates the TLR9/MyD88/IRF7 signalling pathway, inducing anti-viral responses in murine cytomegalovirus models.[3] This TLR-mediated mechanism connects the thymosin peptide to pattern-recognition receptor biology — the frontline system by which the immune system detects and responds to pathogen-associated molecular patterns.
Innate immune enhancement. Serafino et al. (2012) showed that Tα1 stimulates innate cell-mediated immune responses, including macrophage activation and enhanced phagocytic activity through complement receptor-mediated pathways.[4][5] This macrophage-activating property complements the peptide’s effects on adaptive immunity, creating a coordinated immune enhancement profile.
NK cell activity. The thymosin alpha 1 immune profile includes enhancement of natural killer (NK) cell cytotoxicity — a key component of innate immune surveillance against virally infected and transformed cells.[1][8]
Immune System Research
The thymosin alpha 1 immune modulation profile extends across both arms of the immune system, with research documenting effects on innate pathogen defence, adaptive immune priming, and immune homeostasis regulation.[2][4][8]
Innate immunity. Serafino et al. (2014) demonstrated that Tα1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages, establishing a direct mechanism by which the peptide enhances pathogen clearance at the innate immune level.[5] This phagocytic enhancement, combined with TLR-dependent activation of pattern-recognition pathways, positions thymosin alpha-1 as a potent innate immune stimulator.
Adaptive immunity. The peptide’s capacity to promote T-cell maturation and dendritic cell function translates to enhanced adaptive immune responses in preclinical and clinical settings. Pierluigi et al. (2010) characterised Tα1 as “the regulator of regulators” — highlighting its capacity to modulate regulatory T-cell function and immune tolerance alongside its immune-activating properties.[9]
Vaccine adjuvant activity. Tuthill et al. (2012) reviewed the evidence for thymalfasin as a vaccine response enhancer, demonstrating improved seroconversion rates and antibody titres when Tα1 is co-administered with vaccines — particularly in elderly and immunocompromised populations who typically mount suboptimal vaccine responses.[6] This vaccine-adjuvant research has contributed to the regulatory approvals of thymalfasin in multiple countries.
Sepsis and critical illness. King and Tuthill (2015) evaluated thymosin alpha-1 in nonclinical models of immunosuppression, including sepsis — a condition characterised by immune paralysis following initial hyperinflammation. The peptide demonstrated capacity to restore immune function in immunosuppressed states, supporting investigation in critical-care contexts.[10]
Hepatitis B & C Research
Viral hepatitis represents the most extensively studied clinical application of thymosin alpha-1, with multiple randomised controlled trials and regulatory approvals supporting its use in combination therapy for chronic hepatitis B and hepatitis C.[1][8]
Hepatitis B. Clinical trials have demonstrated that thymalfasin, used either as monotherapy or in combination with interferon-alpha, produces sustained virological response and HBeAg seroconversion in patients with chronic hepatitis B. The combination of Tα1 with interferon-alpha has shown improved response rates compared to interferon alone in several controlled trials — a finding that contributed to regulatory approval in over 35 countries.[1][8] The mechanism in hepatitis B involves enhancement of virus-specific T-cell responses and restoration of immune control over viral replication.
Hepatitis C. Similar combination approaches have been evaluated for chronic hepatitis C, with thymosin alpha-1 combined with interferon and ribavirin showing some evidence of enhanced sustained virological response rates in treatment-naïve and treatment-experienced patients. Results have been more variable than in hepatitis B, and the advent of direct-acting antiviral agents has shifted the hepatitis C treatment landscape substantially since much of this research was conducted.[1][8]
Dominari et al. (2020) provided a comprehensive review of the thymosin alpha 1 literature, noting that the hepatitis data remains the strongest evidence base for the peptide’s clinical utility, supported by controlled trials across multiple centres and diverse patient populations.[8]
Cancer Immunotherapy Research
Thymosin alpha-1 has been investigated as an adjunct to cancer immunotherapy, with research exploring its capacity to enhance anti-tumour immune responses when combined with conventional chemotherapy, radiation, or immune checkpoint inhibitors.[7][8][10]
Matteucci et al. (2018) reviewed the cellular biological processes underlying Tα1’s potential in cancer therapy, identifying multiple mechanisms by which the peptide may support anti-tumour immunity: enhanced dendritic cell-mediated tumour antigen presentation, restoration of T-cell function in tumour-suppressive microenvironments, and direct modulation of immune checkpoint pathways.[7]
Clinical investigation has focused on several cancer types:
- Hepatocellular carcinoma (HCC): given the established link between chronic hepatitis B/C and liver cancer, Tα1 has been studied as adjuvant therapy following curative resection of HBV-related HCC, with trials evaluating its capacity to reduce recurrence through enhanced immune surveillance.[8]
- Non-small cell lung cancer: combination studies with chemotherapy have explored whether thymosin alpha 1 can improve immune parameters and clinical outcomes in advanced lung cancer.[7][8]
- Melanoma: King and Tuthill (2015) evaluated Tα1 in preclinical melanoma models, demonstrating immune-mediated anti-tumour effects in immune-suppressive tumour environments.[10]
The cancer immunotherapy evidence for thymosin alpha-1 is promising but remains at an earlier stage than the hepatitis data. Most large-scale controlled trials have been conducted in Asian populations, and regulatory acceptance for oncology indications has been limited. The peptide’s role as an immune-enhancing adjunct — rather than a direct anti-cancer agent — aligns with the broader trend toward combination immunotherapy approaches in oncology research.
Neuroprotection & Longevity Research
Emerging research has begun to explore thymosin alpha-1 beyond its established immunological applications, examining potential neuroprotective and longevity-related properties.[8][9]
Neuroprotection. The peptide’s capacity to modulate neuroinflammatory pathways — through regulation of microglial activation and inflammatory cytokine profiles — has prompted early-stage investigation into neuroprotective applications. Given that chronic neuroinflammation is implicated in neurodegenerative conditions, Tα1’s immunomodulatory profile (rather than direct neuroprotective action) represents the mechanistic basis for this research direction. Evidence remains preclinical and exploratory.
Longevity and immune ageing. Thymic involution — the progressive shrinkage and functional decline of the thymus with age — is a central driver of immune ageing (immunosenescence). As thymic output declines, naïve T-cell production decreases, vaccine responsiveness diminishes, and susceptibility to infections and cancers increases. Thymosin alpha-1’s capacity to enhance T-cell maturation and restore aspects of immune function in aged or immunocompromised populations has positioned it within longevity and healthy-ageing research contexts.[1][6][9] Tuthill et al. (2012) specifically documented the peptide’s capacity to enhance vaccine responses in elderly populations, directly addressing one consequence of immunosenescence.[6]
For related neuroprotection research, see the Semax and Selank profiles. For longevity-focused peptide research, the Longevity & Healthy Aging goal page provides broader context.
Side Effects & Safety Profile
The thymosin alpha 1 side effects profile is generally favourable, reflecting both the extensive clinical trial data (primarily from hepatitis studies) and post-marketing surveillance in countries where thymalfasin is approved.[1][8]
Clinical trial data. Across multiple controlled trials, thymalfasin has demonstrated a safety profile comparable to placebo, with most reported adverse events being mild and transient. The most commonly reported thymosin alpha 1 side effects include injection-site reactions (redness, swelling, mild discomfort), transient flu-like symptoms, and occasional mild gastrointestinal disturbance.[1][8]
Immunological considerations. As an immune-enhancing agent, theoretical concerns exist regarding the potential for excessive immune activation in autoimmune conditions. However, Romani et al. (2007) characterised Tα1 as a regulator of immune tolerance — noting its capacity to promote tolerogenic dendritic cell function alongside immune activation — which may partly explain the absence of significant autoimmune exacerbation in clinical studies.[2]
Drug interactions. Thymosin alpha-1 has been used in combination with interferon-alpha and other immunomodulatory agents without significant adverse interaction profiles in clinical trials. However, the theoretical potential for additive immune stimulation when combined with other immunomodulators warrants consideration in clinical research settings.[1][8]
Post-marketing surveillance. Countries with extensive thymalfasin use (particularly in Asia) have accumulated substantial post-marketing data without identifying significant safety signals beyond those observed in controlled trials. This real-world safety profile across millions of administered doses provides additional confidence, though it primarily reflects usage in viral hepatitis populations.[8]
Thymosin alpha-1 (thymalfasin) is not approved for use in the US or UK. All safety information reflects clinical trial and post-marketing data from jurisdictions where it holds approval. As with all peptides, any investigational use should be conducted under appropriate medical supervision.
Pharmacokinetics
The pharmacokinetic profile of thymosin alpha-1 has been characterised in clinical studies supporting its regulatory approvals.[1][8]
Administration. Thymalfasin is typically administered via subcutaneous injection, achieving systemic absorption with predictable pharmacokinetic behaviour. The subcutaneous route is standard across approved indications and clinical trials.
Half-life. The plasma half-life of thymosin alpha-1 is approximately 2 hours following subcutaneous administration. Despite this relatively short half-life, the immunological effects of Tα1 persist substantially longer than its plasma presence — consistent with a mechanism involving cellular programming (T-cell maturation, dendritic cell activation) rather than sustained receptor occupancy.[1][8]
Distribution. Thymosin alpha-1 distributes systemically following subcutaneous injection, with its immunomodulatory effects documented across multiple organ systems and immune cell populations. As an endogenous peptide, it engages with immune cells throughout the body rather than concentrating at a single target tissue.
Dosing regimens. Approved dosing regimens for thymalfasin typically involve 1.6 mg administered subcutaneously twice weekly, though specific protocols vary by indication and jurisdiction. This twice-weekly dosing schedule reflects the peptide’s mechanism of cellular immune programming rather than continuous receptor modulation.
FAQ
What is thymosin alpha-1?
Thymosin alpha-1 (Tα1) is a 28-amino acid peptide naturally produced in the thymus gland. The thymosin alpha 1 peptide was first isolated from thymic tissue in the 1970s by Allan Goldstein. Its synthetic version, thymalfasin (Zadaxin), is approved in over 35 countries for immune-related conditions including viral hepatitis and as a vaccine adjuvant.[1][8]
What are the benefits of thymosin alpha-1?
Research into thymosin alpha-1 benefits spans immune system enhancement (T-cell maturation, dendritic cell activation, NK cell stimulation), viral hepatitis treatment (improved virological response rates), cancer immunotherapy adjunct effects, vaccine response enhancement in elderly populations, and emerging neuroprotection and longevity investigations. Clinical evidence is strongest for hepatitis B/C applications.[1][2][6][8]
What are the side effects of thymosin alpha-1?
The thymosin alpha 1 side effects documented in clinical trials are generally mild, including injection-site reactions, transient flu-like symptoms, and occasional gastrointestinal disturbance. The safety profile across controlled trials and post-marketing surveillance in approved jurisdictions has been favourable.[1][8]
Is thymosin alpha-1 approved for medical use?
Thymalfasin (synthetic thymosin alpha-1) is approved in over 35 countries — primarily in Asia, South America, and parts of Europe — for chronic hepatitis B/C treatment, vaccine adjuvant use, and immune support. It is not approved by the FDA (US) or MHRA (UK).[1][8]
How does thymosin alpha-1 work for immune support?
The thymosin alpha 1 immune mechanism operates through multiple pathways: promoting T-cell maturation from thymic precursors, activating dendritic cells for enhanced antigen presentation, stimulating Toll-like receptor signalling (particularly TLR2 and TLR9), enhancing macrophage phagocytosis, and boosting NK cell cytotoxicity.[2][3][4][5]
What is the difference between thymosin alpha-1 and TB-500?
Both are members of the thymosin peptide family but serve different functions. Thymosin alpha-1 (from thymosin fraction 5) is primarily an immunomodulatory peptide focused on immune cell maturation and activation. TB-500 is a synthetic fragment of thymosin beta-4 (from thymosin fraction 5’s beta-thymosin component), studied primarily for tissue repair, wound healing, and anti-inflammatory effects.
What is thymalfasin?
Thymalfasin is the International Nonproprietary Name (INN) for synthetic thymosin alpha-1, marketed under the trade name Zadaxin. It is chemically identical to the naturally occurring thymosin alpha 1 peptide and is the form used in all clinical trials and approved therapeutic applications.[1][8]
Can thymosin alpha-1 help with ageing?
Research into thymosin alpha-1 and ageing focuses on its capacity to counteract immunosenescence — the age-related decline in immune function driven partly by thymic involution. By enhancing T-cell maturation and vaccine responsiveness in elderly populations, Tα1 addresses a key mechanism of immune ageing, though dedicated longevity trials have not been conducted.[6][9]
References
- Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther. 2009;9(5):593-608. doi:10.1517/14712590902911412. PMID: 19392576
- Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007;1112:326-338. doi:10.1196/annals.1415.002. PMID: 17495242
- Bozza S, Gaziano R, Bonifazi P, et al. Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int Immunol. 2007;19(11):1261-1270. doi:10.1093/intimm/dxm097. PMID: 17804687
- Serafino A, Pierimarchi P, Pica F, et al. Thymosin α1 as a stimulatory agent of innate cell-mediated immune response. Ann N Y Acad Sci. 2012;1270:13-20. doi:10.1111/j.1749-6632.2012.06707.x. PMID: 23050812
- Serafino A, Pica F, Andreola F, et al. Thymosin α1 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages. J Innate Immun. 2014;6(1):72-88. doi:10.1159/000351587. PMID: 23797159
- Tuthill C, Rios I, De Rosa A, Camerini R. Thymosin α1 continues to show promise as an enhancer for vaccine response. Ann N Y Acad Sci. 2012;1270:21-27. doi:10.1111/j.1749-6632.2012.06680.x. PMID: 23050813
- Matteucci C, Argaw-Denboba A, Balestrieri E, et al. Deciphering cellular biological processes to clinical application: a new perspective for Tα1 treatment targeting multiple diseases. Expert Opin Biol Ther. 2018;18(sup1):23-31. doi:10.1080/14712598.2018.1474198. PMID: 30063863
- Dominari A, Hathaway III D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020;9(5):67-78. doi:10.5501/wjv.v9.i5.67. PMID: 33362999
- Pierluigi B, D’Angelo C, Fallarino F, et al. Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci. 2010;1194:1-5. doi:10.1111/j.1749-6632.2010.05465.x. PMID: 20536444
- King RS, Tuthill C. Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis. Expert Opin Biol Ther. 2015;15 Suppl 1:S41-49. doi:10.1517/14712598.2015.1008446. PMID: 25643200